login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
APTOSE BIOSCIENCES INC (APTO) Stock News
NASDAQ:APTO -
CA03835T4081
-
Common Stock
1.71
USD
-1.44 (-45.71%)
Last: 4/1/2025, 8:17:01 PM
2.16
USD
+0.45 (+26.32%)
After Hours:
4/1/2025, 8:17:01 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
APTO Latest News, Press Relases and Analysis
All
Press Releases
4 months ago - By: Aptose Biosciences, Inc.
- Mentions:
APS.CA
Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial
4 months ago - By: Aptose Biosciences, Inc.
- Mentions:
APS.CA
Aptose Announces Auditor Not Standing for Re-Appointment
4 months ago - By: Aptose Biosciences, Inc.
- Mentions:
APS.CA
Aptose Announces Auditor Not Standing for Re-Appointment
4 months ago - By: Aptose Biosciences, Inc.
- Mentions:
APS.CA
Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
5 months ago - By: Benzinga
Why Aptose Biosciences (APTO) Stock Is Down Over 40%
4 months ago - By: Aptose Biosciences, Inc.
- Mentions:
APS.CA
Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
5 months ago - By: Benzinga
- Mentions:
PVH
CMBM
LPRO
MVST
...
Nasdaq Surges 1%; US Construction Spending Rises In February
5 months ago - By: Aptose Biosciences, Inc.
- Mentions:
APS.CA
Aptose Common Shares to Delist from Nasdaq as of April 2, 2025
5 months ago - By: Aptose Biosciences, Inc.
- Mentions:
APS.CA
Aptose Common Shares to Delist from Nasdaq as of April 2, 2025
5 months ago - By: Yahoo Finance
- Mentions:
ICON
LTRY
META
ETR
...
Icon Energy to effect 1-for-40 reverse stock split
5 months ago - By: Yahoo Finance
- Mentions:
MIST
WGO
BRZE
IDXX
...
Milestone CRL affirms integrity of clinical data, says H.C. Wainwright
5 months ago - By: Yahoo Finance
- Mentions:
RJF
WFC
BRZE
LVLU
...
Braze price target raised to $55 from $50 at Citi
5 months ago - By: Yahoo Finance
- Mentions:
WFC
HUMA
LVLU
MTB
...
Humacyte price target lowered to $8 from $10 at BTIG
5 months ago - By: Yahoo Finance
- Mentions:
WFC
LVLU
HUMA
MTB
...
Lulu’s Fashion Lounge price target lowered to $1 from $2 at Telsey Advisory
5 months ago - By: Yahoo Finance
- Mentions:
MELI
BKNG
NVDA
CIEN
...
Stock Split Watch: Are These 2 Unstoppable Stocks Next?
5 months ago - By: Aptose Biosciences, Inc.
- Mentions:
APS.CA
Aptose Reports Year End 2024 Results and Corporate Highlights
5 months ago - By: Aptose Biosciences, Inc.
- Mentions:
APS.CA
Aptose Reports Year End 2024 Results and Corporate Highlights
6 months ago - By: Aptose Biosciences, Inc.
- Mentions:
APS.CA
Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
6 months ago - By: Aptose Biosciences, Inc.
- Mentions:
APS.CA
Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
7 months ago - By: Aptose Biosciences, Inc.
- Mentions:
APS.CA
Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort
7 months ago - By: Aptose Biosciences, Inc.
- Mentions:
APS.CA
Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort
Please enable JavaScript to continue using this application.